CoronaryAtlas logo
CoronaryAtlas
Ischemia-modified albumin
Pathway / Myocardial injury (shared endpoint)

Ischemia-modified albumin

ALBprotein

Ischemia-modified albumin (IMA) is an early albumin modification arising from myocardial ischemia that serves as a sensitive early ACS biomarker preceding troponin elevation.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleEarly post-translational modification marker of myocardial ischemia.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000163631

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
50
A — assay feasibility
84
E — evidence strength
65
T1DI (composite)
32
Specificity differential (R−C)+16.7
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 1
3hypovolemia / dehydrationmag 2
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 1
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma; urine (microalbumin)
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
Dye-binding (BCG/BCP) or immunoturbidimetric (urine)
Reagent / substrate
Bromocresol green/purple; anti-albumin latex for urine
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Human genetic evidence

0.018
Open Targets association (STEMI)

Literature evidence(7)